Table 2.
Cox regression models for the association of the TyG index and SHR with clinical outcomes
| Per one unit increasea | Groups | P for trend | |||
|---|---|---|---|---|---|
| T1 | T2 | T3 | |||
| TyG index | |||||
| CV death and TVMI | |||||
| No/Subject | 7/895 | 13/917 | 27/928 | ||
| Crude | 1.67 (1.15–2.43) | 1.00 | 1.78 (0.71–4.47) | 3.74 (1.62–8.56) | 0.001 |
| Model 1 | 1.94 (1.30–2.90) | 1.00 | 2.05 (0.81–5.16) | 4.76 (2.04–11.11) | < 0.001 |
| Model 2 | 2.15 (1.36–3.40) | 1.00 | 1.90 (0.75–4.83) | 5.07 (2.10–12.23) | < 0.001 |
| Model 3 | 1.97 (1.19–3.27) | 1.00 | 1.48 (0.53–4.09) | 4.23 (1.58–11.37) | 0.004 |
| MACCEs | |||||
| No/Subject | 40/895 | 56/917 | 83/928 | ||
| Crude | 1.50 (1.23–1.82) | 1.00 | 1.10 (0.72–1.68) | 2.04 (1.40–2.98) | < 0.001 |
| Model 1 | 1.62 (1.32–2.00) | 1.00 | 1.19 (0.77–1.82) | 2.35 (1.60–3.45) | < 0.001 |
| Model 2 | 1.67 (1.34–2.08) | 1.00 | 1.17 (0.76–1.79) | 2.46 (1.64–3.68) | < 0.001 |
| Model 3 | 1.73 (1.34–2.24) | 1.00 | 1.31 (0.81–2.14) | 2.47 (1.54–3.97) | < 0.001 |
| SHR | |||||
| CV death and TVMI | |||||
| No/Subject | 5/897 | 15/911 | 27/932 | ||
| Crude | 1.28 (1.15–1.41) | 1.00 | 2.94 (1.07–8.08) | 5.18 (1.99–13.45) | < 0.001 |
| Model 1 | 1.25 (1.14–1.38) | 1.00 | 3.09 (1.12–8.51) | 5.54 (2.13–14.40) | < 0.001 |
| Model 2 | 1.29 (1.15–1.44) | 1.00 | 2.88 (1.04–8.01) | 5.70 (2.16–15.04) | < 0.001 |
| Model 3 | 1.22 (1.14–1.32) | 1.00 | 2.53 (0.87–7.39) | 5.14 (1.89–13.98) | 0.001 |
| MACCEs | |||||
| No/Subject | 31/897 | 48/911 | 90/932 | ||
| Crude | 1.23 (1.16–1.30) | 1.00 | 1.51 (0.96–2.37) | 2.87 (1.91–4.32) | < 0.001 |
| Model 1 | 1.22 (1.15–1.29) | 1.00 | 1.56 (0.99–2.45) | 2.98 (1.98–4.48) | < 0.001 |
| Model 2 | 1.23 (1.16–1.32) | 1.00 | 1.55 (0.98–2.44) | 3.04 (2.01–4.61) | < 0.001 |
| Model 3 | 1.26 (1.11–1.44) | 1.00 | 1.58 (0.96–2.59) | 2.91 (1.84–4.60) | < 0.001 |
Model 1: adjusted for age, sex, and BMI
Model 2: adjusted for age, sex, BMI, smoking, T2DM, dyslipidemia, hypertension, prior HF, prior MI, prior stroke, peripheral vascular disease, prior revascularization, and AMI
Model 3: adjusted for age, sex, BMI, smoking, HF, T2DM, dyslipidemia, hypertension, prior MI, prior stroke, peripheral vascular disease, prior revascularization, AMI, multivessel disease, ostial lesion, bifurcation, number of lesions ≥ 2, number of stents ≥ 2, procedural success, eGFR, DAPT, statin, and anti-diabetic drug
TyG triglyceride-glucose, CV cardiovascular, eGFR estimated glomerular filtration rate, MI myocardial infarction, MACCEs major adverse cardiovascular cerebral events, SHR stress-hyperglycemia ratio, BMI body mass index, T2DM type 2 diabetes mellitus, HF heart failure, AMI acute myocardial infarction, DAPT dual anti-platelet therapy
aPer one unit refers to “1.00” in the Tyg index and “0.10” in SHR